{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:24:26Z","timestamp":1784823866343,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-02050-5","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T19:01:35Z","timestamp":1684954895000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Isorhamnetin exerts anti-tumor activity in DEN\u2009+\u2009CCl4-induced HCC mice"],"prefix":"10.1007","volume":"40","author":[{"given":"Sayanta","family":"Sarkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek Kumar","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semantee","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratan","family":"Gachhui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0190-5904","authenticated-orcid":false,"given":"Parames C.","family":"Sil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"issue":"3","key":"2050_CR1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2050_CR2","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s12262-021-02762-w","volume":"83","author":"HJ Chavda","year":"2021","unstructured":"Chavda HJ. Hepatocellular carcinoma in India. Indian J Surg. 2021;83(4):959\u201366.","journal-title":"Indian J Surg"},{"issue":"15","key":"2050_CR3","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450\u201362.","journal-title":"N Engl J Med"},{"issue":"10","key":"2050_CR4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","volume":"15","author":"JM Llovet","year":"2018","unstructured":"Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599\u2013616.","journal-title":"Nat Rev Clin Oncol"},{"key":"2050_CR5","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5794350","volume":"2022","author":"YO Ali Abdalla","year":"2022","unstructured":"Ali Abdalla YO, Subramaniam B, Nyamathulla S, Shamsuddin, et al. Natural products for cancer therapy: a review of their mechanism of actions and toxicity in the past decade. J Trop Med. 2022;2022: e5794350.","journal-title":"J Trop Med"},{"key":"2050_CR6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122555","volume":"631","author":"N Ghosh","year":"2023","unstructured":"Ghosh N, Kundu M, Ghosh S, Das AK, De S, Das J, Sil PC. pH-responsive and targeted delivery of chrysin via folic acid-functionalized mesoporous silica nanocarrier for breast cancer therapy. Int J Pharm. 2023;631: 122555.","journal-title":"Int J Pharm"},{"key":"2050_CR7","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2019.103927","volume":"140","author":"D Bhattacharya","year":"2020","unstructured":"Bhattacharya D, Sinha R, Mukherjee P, et al. Anti-virulence activity of polyphenolic fraction isolated from Kombucha against Vibrio cholerae. Microb Pathog. 2020;140: 103927.","journal-title":"Microb Pathog"},{"key":"2050_CR8","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110301","volume":"128","author":"G Gong","year":"2020","unstructured":"Gong G, Guan YY, Zhang ZL, Rahman K, et al. Isorhamnetin: a review of pharmacological effects. Biomed Pharmacother. 2020;128: 110301.","journal-title":"Biomed Pharmacother"},{"key":"2050_CR9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11130-014-0438-5","volume":"69","author":"M Antunes-Ricardo","year":"2014","unstructured":"Antunes-Ricardo M, Moreno-Garc\u00eda BE, Guti\u00e9rrez-Uribe JA, et al. Induction of apoptosis in colon cancer cells treated with isorhamnetin glycosides from Opuntia ficus-indica pads. Plant Foods Hum Nutr. 2014;69:331\u20136.","journal-title":"Plant Foods Hum Nutr"},{"issue":"5","key":"2050_CR10","doi-asserted-by":"crossref","first-page":"6745","DOI":"10.3892\/mmr.2015.4269","volume":"12","author":"S Hu","year":"2015","unstructured":"Hu S, Huang L, Meng L, et al. Isorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer via Akt and mitogen-activated protein kinase kinase signaling pathways. Mol Med Rep. 2015;12(5):6745\u201351.","journal-title":"Mol Med Rep"},{"issue":"16","key":"2050_CR11","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.3390\/molecules27165191","volume":"27","author":"Y Li","year":"2022","unstructured":"Li Y, Fan B, Pu N, et al. Isorhamnetin suppresses human gastric cancer cell proliferation through mitochondria-dependent apoptosis. Molecules. 2022;27(16):5191.","journal-title":"Molecules"},{"issue":"1","key":"2050_CR12","first-page":"25","volume":"8","author":"BY Zhang","year":"2015","unstructured":"Zhang BY, Wang YM, Gong H, et al. Isorhamnetin flavonoid synergistically enhances the anticancer activity and apoptosis induction by cis-platin and carboplatin in non-small cell lung carcinoma (NSCLC). Int J Clin Exp Pathol. 2015;8(1):25\u201337.","journal-title":"Int J Clin Exp Pathol"},{"key":"2050_CR13","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.biopha.2018.04.016","volume":"103","author":"X Lu","year":"2018","unstructured":"Lu X, Liu T, Chen K, et al. Isorhamnetin: a hepatoprotective flavonoid inhibits apoptosis and autophagy via P38\/PPAR-\u03b1 pathway in mice. Biomed Pharmacother. 2018;103:800\u201311.","journal-title":"Biomed Pharmacother"},{"key":"2050_CR14","first-page":"1","volume":"2019","author":"N Liu","year":"2019","unstructured":"Liu N, Feng J, Lu X, et al. Isorhamnetin inhibits liver fibrosis by reducing autophagy and inhibiting extracellular matrix formation via the TGF-\u03b21\/Smad3 and TGF-\u03b21\/p38 MAPK pathways. Mediat Inflamm. 2019;2019:1\u201314.","journal-title":"Mediat Inflamm."},{"issue":"2","key":"2050_CR15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.taap.2013.10.026","volume":"274","author":"JH Yang","year":"2014","unstructured":"Yang JH, Shin BY, Han JY, Kim MG, Wi JE, Kim YW, et al. Isorhamnetin protects against oxidative stress by activating Nrf2 and inducing the expression of its target genes. Toxicol Appl Pharmacol. 2014;274(2):293\u2013301.","journal-title":"Toxicol Appl Pharmacol"},{"key":"2050_CR16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/0471141755.ph1430s66","volume":"66","author":"T Uehara","year":"2014","unstructured":"Uehara T, Pogribny IP, Rusyn I. The DEN and CCl4 -induced mouse model of fibrosis and inflammation-associated hepatocellular carcinoma. Curr Protoc Pharmacol. 2014;66:14\u201330.","journal-title":"Curr Protoc Pharmacol"},{"key":"2050_CR17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jnutbio.2015.08.016","volume":"27","author":"S Sur","year":"2016","unstructured":"Sur S, Pal D, Mandal S, Roy A, Panda CK. Tea polyphenols epigallocatechin gallete and theaflavin restrict mouse liver carcinogenesis through modulation of self-renewal Wnt and hedgehog pathways. J Nutr Biochem. 2016;27:32\u201342.","journal-title":"J Nutr Biochem"},{"issue":"7","key":"2050_CR18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5897\/JMPR2018.6561","volume":"12","author":"R Fei","year":"2018","unstructured":"Fei R, Wei H. Quantitative proteomic analysis of Isorhamnetin treatment in human liver cancer cells. J Med Plants. 2018;12(7):77\u201388.","journal-title":"J Med Plants."},{"issue":"3","key":"2050_CR19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.phrs.2006.04.007","volume":"54","author":"BS Teng","year":"2006","unstructured":"Teng BS, Lu YH, Wang ZT, et al. In vitro anti-tumor activity of isorhamnetin isolated from Hippophae rhamnoides L. against BEL-7402 cells. Pharmacol Res. 2006;54(3):186\u201394.","journal-title":"Pharmacol Res"},{"issue":"10","key":"2050_CR20","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3390\/cancers11101494","volume":"11","author":"C Park","year":"2019","unstructured":"Park C, Cha HJ, Choi EO, et al. Isorhamnetin induces cell cycle arrest and apoptosis via reactive oxygen species-mediated AMP-activated protein kinase signaling pathway activation in human bladder cancer cells. Cancers. 2019;11(10):1494.","journal-title":"Cancers"},{"issue":"3","key":"2050_CR21","doi-asserted-by":"crossref","first-page":"BSR20192826","DOI":"10.1042\/BSR20192826","volume":"40","author":"F Cai","year":"2020","unstructured":"Cai F, Zhang Y, Li J, et al. Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K\/Akt\/mTOR pathway. Biosci Rep. 2020;40(3):BSR20192826.","journal-title":"Biosci Rep."},{"issue":"45","key":"2050_CR22","doi-asserted-by":"crossref","first-page":"38028","DOI":"10.1074\/jbc.M112.388702","volume":"287","author":"L Ramachandran","year":"2012","unstructured":"Ramachandran L, Manu KA, Shanmugam MK, et al. Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor \u03b3 activation pathway in gastric cancer. J Biol Chem. 2012;287(45):38028\u201340.","journal-title":"J Biol Chem"},{"issue":"5","key":"2050_CR23","volume":"8","author":"J Sun","year":"2013","unstructured":"Sun J, Sun G, Meng X, et al. Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro. PLoS ONE. 2013;8(5): e64526.","journal-title":"PLoS ONE"},{"key":"2050_CR24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00432-009-0658-5","volume":"136","author":"C Jin","year":"2010","unstructured":"Jin C, Li H, He Y, et al. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo. J Cancer Res Clin Oncol. 2010;136:267\u201374.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"2050_CR25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1742-7843.2007.00132.x","volume":"101","author":"P Manna","year":"2007","unstructured":"Manna P, Sinha M, Sil PC. Protection of arsenic-induced hepatic disorder by arjunolic acid. Basic Clin Pharmacol Toxicol. 2007;101(5):333\u20138.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2050_CR26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.fct.2016.09.011","volume":"97","author":"S Chowdhury","year":"2016","unstructured":"Chowdhury S, Ghosh S, Rashid K, Sil PC. Deciphering the role of ferulic acid against streptozotocin-induced cellular stress in the cardiac tissue of diabetic rats. Food Chem Toxicol. 2016;97:187\u201398.","journal-title":"Food Chem Toxicol"},{"key":"2050_CR27","volume":"305","author":"AK Das","year":"2022","unstructured":"Das AK, Hossain U, Ghosh S, et al. Amelioration of oxidative stress mediated inflammation and apoptosis in pancreatic islets by Lupeol in STZ-induced hyperglycaemic mice. Life Sci. 2022;305: 120769.","journal-title":"Life Sci"},{"issue":"3","key":"2050_CR28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cbi.2009.08.004","volume":"181","author":"P Manna","year":"2009","unstructured":"Manna P, Sinha M, Sil PC. Prophylactic role of arjunolic acid in response to streptozotocin mediated diabetic renal injury: activation of polyol pathway and oxidative stress responsive signaling cascades. Chem Biol Interact. 2009;181(3):297\u2013308.","journal-title":"Chem Biol Interact"},{"issue":"2","key":"2050_CR29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.taap.2009.12.024","volume":"244","author":"P Manna","year":"2010","unstructured":"Manna P, Ghosh J, Das J, Sil PC. Streptozotocin induced activation of oxidative stress responsive splenic cell signaling pathways: protective role of arjunolic acid. Toxicol Appl Pharmacol. 2010;244(2):114\u201329.","journal-title":"Toxicol Appl Pharmacol"},{"key":"2050_CR30","first-page":"313","volume":"5","author":"S Saha","year":"2016","unstructured":"Saha S, Sadhukhan P, Sinha K, Agarwal N, Sil PC. Mangiferin attenuates oxidative stress induced renal cell damage through activation of PI3K induced Akt and Nrf-2 mediated signaling pathways. Biochem Biophys Rep. 2016;5:313\u201327.","journal-title":"Biochem Biophys Rep."},{"key":"2050_CR31","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120606","volume":"301","author":"N Ghosh","year":"2022","unstructured":"Ghosh N, Chatterjee S, Biswal D, Pramanik NR, Chakrabarti S, Sil PC. Oxidative stress imposed in vivo anticancer therapeutic efficacy of novel imidazole-based oxidovanadium (IV) complex in solid tumor. Life Sci. 2022;301: 120606.","journal-title":"Life Sci"},{"issue":"16","key":"2050_CR32","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.3748\/wjg.v22.i16.4091","volume":"22","author":"A Ambade","year":"2016","unstructured":"Ambade A, Satishchandran A, Gyongyosi B, et al. Adult mouse model of early hepatocellular carcinoma promoted by alcoholic liver disease. World J Gastroenterol. 2016;22(16):4091.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"2050_CR33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/cncy.21190","volume":"120","author":"M Fujiwara","year":"2012","unstructured":"Fujiwara M, Kwok S, Yano H, Pai RK. Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies. Cancer Cytopathol. 2012;120(4):230\u20137.","journal-title":"Cancer Cytopathol"},{"key":"2050_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1746-1596-7-149","volume":"7","author":"NA Radwan","year":"2012","unstructured":"Radwan NA, Ahmed NS. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1. Diagnostic Pathol. 2012;7:1\u201312.","journal-title":"Diagnostic Pathol"},{"issue":"1","key":"2050_CR35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2050_CR36","first-page":"529","volume":"16","author":"W Li","year":"2018","unstructured":"Li W, Jian YB. Antitumor necrosis factor-alpha antibodies as a noveltherapy for hepatocellular carcinoma. Exp Ther Med. 2018;16(2):529\u201336.","journal-title":"Exp Ther Med"},{"issue":"2","key":"2050_CR37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cell.2008.11.017","volume":"136","author":"M Das","year":"2009","unstructured":"Das M, Sabio G, Jiang F, et al. Induction of hepatitis by JNK-mediated expression of TNF-\u03b1. Cell. 2009;136(2):249\u201360.","journal-title":"Cell"},{"issue":"2","key":"2050_CR38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0092-8674(03)00042-4","volume":"112","author":"R Eferl","year":"2003","unstructured":"Eferl R, Ricci R, Kenner L, et al. Liver tumor development: c-Jun antagonizes the proapoptotic activity of p53. Cell. 2003;112(2):181\u201392.","journal-title":"Cell"},{"issue":"11","key":"2050_CR39","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1210\/en.2004-0180","volume":"145","author":"M Kudo","year":"2004","unstructured":"Kudo M, Sugawara A, Uruno A, et al. Transcription suppression of peroxisome proliferator-activated receptor \u03b32 gene expression by tumor necrosis factor \u03b1 via an inhibition of CCAAT\/enhancer-binding protein \u03b4 during the early stage of adipocyte differentiation. Endocrinology. 2004;145(11):4948\u201356.","journal-title":"Endocrinology"},{"issue":"8","key":"2050_CR40","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1074\/jbc.272.8.5128","volume":"272","author":"M Adams","year":"1997","unstructured":"Adams M, Reginato MJ, Shao D, et al. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem. 1997;272(8):5128\u201332.","journal-title":"J Biol Chem"},{"key":"2050_CR41","first-page":"127","volume":"1","author":"HT Hsu","year":"2014","unstructured":"Hsu HT, Chi CW. Emerging role of the peroxisome proliferator-activated receptor-gamma in hepatocellular carcinoma. J Hepatocell Carcinoma. 2014;1:127\u201335.","journal-title":"J Hepatocell Carcinoma."},{"key":"2050_CR42","doi-asserted-by":"crossref","first-page":"9423907","DOI":"10.1155\/2019\/9423907","volume":"2019","author":"C Scheau","year":"2019","unstructured":"Scheau C, Badarau IA, Costache R, et al. The role of matrix metalloproteinases in the epithelial-mesenchymal transition of hepatocellular carcinoma. Anal Cell Pathol. 2019;2019:9423907.","journal-title":"Anal Cell Pathol"},{"issue":"9","key":"2050_CR43","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/bjc.2012.130","volume":"106","author":"B Shen","year":"2012","unstructured":"Shen B, Chu ES, Zhao G, et al. PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice. Br J Cancer. 2012;106(9):1486\u201394.","journal-title":"Br J Cancer"},{"key":"2050_CR44","doi-asserted-by":"crossref","unstructured":"Sarkar S, Ghosh N, Kundu M, Sil PC (2020) Nrf2 and Inflammation-Triggered Carcinogenesis. In: Deng H (eds) Nrf2 and its Modulation in Inflammation. Progress in Inflammation Research, vol 85th. Springer, Cham, pp 129\u2013152.","DOI":"10.1007\/978-3-030-44599-7_6"},{"issue":"4","key":"2050_CR45","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.molcel.2009.08.002","volume":"35","author":"U Doehn","year":"2009","unstructured":"Doehn U, Hauge C, Frank SR, et al. RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile\/invasive gene program and phenotype in epithelial cells. Mol Cell. 2009;35(4):511\u201322.","journal-title":"Mol Cell"},{"issue":"9","key":"2050_CR46","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1158\/0008-5472.CAN-16-3242","volume":"77","author":"J Tong","year":"2017","unstructured":"Tong J, Wang P, Tan S, et al. Mcl-1 degradation is required for targeted therapeutics to eradicate colon cancer cells. Cancer Res. 2017;77(9):2512\u201321.","journal-title":"Cancer Res"},{"issue":"14","key":"2050_CR47","first-page":"5389","volume":"61","author":"NG Deane","year":"2001","unstructured":"Deane NG, Parker MA, Aramandla R, et al. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res. 2001;61(14):5389\u201395.","journal-title":"Cancer Res"},{"issue":"10","key":"2050_CR48","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/cr.2007.86","volume":"17","author":"U Kossatz","year":"2007","unstructured":"Kossatz U, Malek NP. p27: tumor suppressor and oncogene \u2026? Cell Res. 2007;17(10):832\u20133.","journal-title":"Cell Res"},{"issue":"4","key":"2050_CR49","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/hupa.2002.124724","volume":"33","author":"H Wagayama","year":"2002","unstructured":"Wagayama H, Shiraki K, Sugimoto K, et al. High expression of p21WAF1\/CIP1 is correlated with human hepatocellular carcinoma in patients with hepatitis C virus-associated chronic liver diseases. Hum Pathol. 2002;33(4):429\u201334.","journal-title":"Hum Pathol"},{"issue":"8","key":"2050_CR50","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1478-3231.2006.01320.x","volume":"26","author":"K Shiraki","year":"2006","unstructured":"Shiraki K, Wagayama H. Cytoplasmic p21(WAF1\/CIP1) expression in human hepatocellular carcinomas. Liver Int. 2006;26(8):1018\u20139.","journal-title":"Liver Int"},{"key":"2050_CR51","volume":"207","author":"AK Das","year":"2022","unstructured":"Das AK, Ghosh N, Mandal A, Sil PC. Glycobiology of cellular expiry: decrypting the role of glycan-lectin regulatory complex and therapeutic strategies focusing on cancer. Biochem Pharmacol. 2022;207: 115367.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2050_CR52","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1038\/s41467-018-07338-z","volume":"9","author":"YA Lee","year":"2018","unstructured":"Lee YA, Noon LA, Akat KM, et al. Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. Nat Commun. 2018;9(1):4962.","journal-title":"Nat Commun"},{"issue":"1","key":"2050_CR53","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/nyas.14027","volume":"1443","author":"N Ghosh","year":"2019","unstructured":"Ghosh N, Hossain U, Mandal A, Sil PC. The Wnt signaling pathway: a potential therapeutic target against cancer. Ann N Y Acad Sci. 2019;1443(1):54\u201374.","journal-title":"Ann N Y Acad Sci"},{"key":"2050_CR54","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ebiom.2018.12.047","volume":"40","author":"W Tan","year":"2019","unstructured":"Tan W, Luo X, Li W, et al. TNF-alpha is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma. EBioMedicine. 2019;40:446\u201356.","journal-title":"EBioMedicine"},{"issue":"3","key":"2050_CR55","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.bbrc.2008.07.068","volume":"374","author":"J Ye","year":"2008","unstructured":"Ye J. Regulation of PPARgamma function by TNF-alpha. Biochem Biophys Res Commun. 2008;374(3):405\u20138.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02050-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-02050-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02050-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T23:02:17Z","timestamp":1702508537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-02050-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":55,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["2050"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-02050-5","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,24]]},"assertion":[{"value":"10 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"All the animal experiments were prosecuted according to the institutional ethical committee and with the permission of IAEC, CPCSEA (Committee for the Purpose of Control & Supervision on Experiments on Animals) and the Ministry of Environment and Forests, New Delhi, India [1796\/GO\/EReBiBt\/S\/14\/CPCSEA].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"188"}}